COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk We conducted a two-round modified Delphi survey. Participants were patients (or their carers) who had ...

Older patients receiving immune checkpoint inhibitors for early-stage breast cancer may have increased risk of high-grade immune-related side effects. The study found 72.6% of patients experienced any ...

Cancer represents a key challenge in medical science, manifesting as a disease where the immune system fails to recognize and eliminate tumor cells. The phenomenon of immune evasion by cancer cells ...

PHOENIX — Patients treated for cancer with immune checkpoint inhibitors (ICIs) who develop the drugs’ known side effects of diarrhea and colitis experience increased risk of adenomas in the colon — ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Bottom Line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...